UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real world data on treatment of chromophobe renal cell carcinoma

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.409-409

2024

Volltextzugriff (PDF)

Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.445-445

2024

Volltextzugriff (PDF)

A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4541-4541

2024

Volltextzugriff (PDF)

STARLITE 2: Phase 2 study of nivolumab plus 177 lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( 177 Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS752-TPS752

2023

Volltextzugriff (PDF)

STARLITE 2: Phase 2 study of nivolumab plus 177 Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( 177 Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4603-TPS4603

2022

Volltextzugriff (PDF)

A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4558-4558

2022

Volltextzugriff (PDF)

Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4545-4545

2023

Volltextzugriff (PDF)

Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS399-TPS399

2022

Volltextzugriff (PDF)

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.687-687

2023

Volltextzugriff (PDF)

Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.659-659

2023

Volltextzugriff (PDF)

Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.720-720

2023

Volltextzugriff (PDF)

Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4571-4571

2024

Volltextzugriff (PDF)

Comparative circulating tumor DNA (ctDNA) genomic profiling in 110 patients with advanced renal cell carcinoma

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.743-743

2020

Volltextzugriff (PDF)

CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS370-TPS370

2021

Volltextzugriff (PDF)

A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.323-323

2021

Volltextzugriff (PDF)

PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS403-TPS403

2022

Volltextzugriff (PDF)

First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.2-2

2024

Volltextzugriff (PDF)

Long-term outcomes of adrenal insufficiency (AI) due to anti–PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.12092-12092

2022

Volltextzugriff (PDF)

Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4514-4514

2022

Volltextzugriff (PDF)

Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4536-4536

2022

Volltextzugriff (PDF)

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4598-4598

2023

Volltextzugriff (PDF)

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4537-4537

2023

Volltextzugriff (PDF)

A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.347-347

2022

Volltextzugriff (PDF)

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA4500-LBA4500

2023

Volltextzugriff (PDF)

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4534-4534

2023

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Aktive Filter

ThemaAged

ThemaOncology

ThemaTargeted Cancer Therapy

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

Real world data on treatment of chromophobe renal cell carcinoma

Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma

A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma

STARLITE 2: Phase 2 study of nivolumab plus 177 lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( 177 Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

STARLITE 2: Phase 2 study of nivolumab plus 177 Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ( 177 Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC

Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma

Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations

Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214

Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade

Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB)

Comparative circulating tumor DNA (ctDNA) genomic profiling in 110 patients with advanced renal cell carcinoma

CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma

A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma

PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC)

First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study

Long-term outcomes of adrenal insufficiency (AI) due to anti–PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer

Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study

Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial

A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Aktive Filter

Suchergebnisse filtern